| Kezar Life Sciences Inc (KZR) | |||
|---|---|---|---|
| 0.8378 0.033 (4.09%) | 04-29 16:00 | ||
| Open: | 0.82 | Pre. Close: | 0.8049 |
| High: | 0.85 | Low: | 0.8103 |
| Volume: | 579,343 | Market Cap: | 61(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 1.06  One year: 1.18 |
| Support: | Support1: 0.75 Support2: 0.62 |
| Resistance: | Resistance1: 0.91 Resistance2: 1.01 |
| Pivot: | 0.81 |
| Moving Averages: | MA(5): 0.81 MA(20): 0.82 MA(100): 0.89 MA(250): 1.41 |
| MACD: | MACD(12,26): -0.02 Signal(12,26,9): -0.03 |
| %K %D: | %K(14,3): 41.38 %D(3): 38.57 |
| RSI: | RSI(14): 49.79 |
| 52-Week: | High: 3.13 Low: 0.67 Change(%): -66.4 |
| Average Vol(K): | 3-Month: 783 10-Days: 528 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 0.851 - 0.854 | 0.854 - 0.858 |
| Low: | 0.801 - 0.805 | 0.805 - 0.809 |
| Close: | 0.833 - 0.839 | 0.839 - 0.846 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KZR ] has closed below upper band by 26.0%. Bollinger Bands are 48% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 72.80 |
| % Held by Insiders | 52500000.00 |
| % Held by Institutions | 14.81 |
| Shares Short (K) | 3180 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -104170000.000 |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | 503.4 |
| Return on Equity (ttm) | -25.3 |
| Qtrly Rev. Growth | 7000000.0 |
| Gross Profit (p.s.) | |
| Sales Per Share | -96.826 |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | -1.40 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -81.64 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.15 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 3570000.000 |
